Get the Stockscreener App
5.212
3.29%
-0.178
Corvus Pharmaceuticals Inc stock is traded at $5.212, with a volume of 124.84K.
It is down -3.29% in the last 24 hours and down -9.34% over the past month.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
See More
Previous Close:
$5.39
Open:
$5.39
24h Volume:
124.84K
Relative Volume:
0.13
Market Cap:
$346.35M
Revenue:
-
Net Income/Loss:
$-27.03M
P/E Ratio:
-9.3071
EPS:
-0.56
Net Cash Flow:
$-23.97M
1W Performance:
-2.75%
1M Performance:
-9.34%
6M Performance:
+58.44%
1Y Performance:
+151.82%
1-Day Range:
$5.20
$5.56
1-Week Range:
$5.02
$5.65
52-Week Range:
$1.30
$10.00
Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile
Name
Corvus Pharmaceuticals Inc
Sector
Industry
Phone
(650) 900-4520
Address
863 MITTEN ROAD, BURLINGAME, CA
Compare CRVS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRVS
Corvus Pharmaceuticals Inc
|
5.2122 | 346.35M | 0 | -27.03M | -23.97M | -0.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.46 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.63 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
652.19 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.24 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.75 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-02-25 | Initiated | H.C. Wainwright | Buy |
| Aug-18-23 | Initiated | Oppenheimer | Outperform |
| Dec-01-21 | Resumed | Jefferies | Buy |
| May-27-21 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-10-21 | Downgrade | Mizuho | Buy → Neutral |
| Sep-12-19 | Initiated | Mizuho | Buy |
| May-29-19 | Initiated | ROTH Capital | Buy |
| Aug-24-17 | Upgrade | Credit Suisse | Underperform → Neutral |
| May-01-17 | Downgrade | Credit Suisse | Neutral → Underperform |
| Apr-18-16 | Initiated | Credit Suisse | Outperform |
| Apr-18-16 | Initiated | Guggenheim | Buy |
View All
Corvus Pharmaceuticals Inc Stock (CRVS) Latest News
Corvus Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - The Manila Times
Exclusive Healthcare Insights: Corvus Pharma Takes Center Stage at Major Oppenheimer Conference - StockTitan
JPMorgan Chase & Co. Buys 40,404 Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) - Defense World
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives $12.38 Average Target Price from Analysts - Defense World
Analysts Set Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) PT at $12.38 - MarketBeat
Cantor Fitzgerald Comments on CRVS FY2025 Earnings - Defense World
When (CRVS) Moves Investors should Listen - Stock Traders Daily
Equities Analysts Offer Predictions for CRVS FY2025 Earnings - MarketBeat
CRVS’s Stock Market Adventure: -8.04% YTD Growth Amidst Volatility - The InvestChronicle
Corvus Pharmaceuticals (NASDAQ: CRVS) Announces Positive Interim Data from Phase 1 Clinical Trial of Soquelitinib for Atopic DermatitisOn January 13, 2025, Corvus Pharmaceuticals, a clinical-stage biopharmaceutical company, released encouraging int - Defense World
HC Wainwright Reiterates "Buy" Rating for Corvus Pharmaceuticals (NASDAQ:CRVS) - MarketBeat
HC Wainwright & Co. Initiates Coverage of Corvus Pharmaceuticals (CRVS) with Buy Recommendation - MSN
Corvus Pharmaceuticals Reports Promising Interim Data on Soquelitinib - TipRanks
Corvus reports hopeful data on eczema drug trial - Investing.com India
Corvus reports hopeful data on eczema drug trial By Investing.com - Investing.com Australia
Corvus Pharmaceuticals Announces Data from Cohort 2 of - GlobeNewswire
Corvus Pharmaceuticals Announces Data from Cohort 2 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis - Yahoo Finance
50,221 Shares in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Bought by Jane Street Group LLC - Defense World
Geode Capital Management LLC Purchases 102,869 Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) - MarketBeat
Geode Capital Management LLC Increases Stake in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) - Defense World
Corvus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Corvus Pharmaceuticals CEO to Present Corporate Overview at J.P. Morgan Healthcare Conference - StockTitan
We're Not Worried About Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn - Yahoo Finance
What is HC Wainwright’s Forecast for CRVS FY2024 Earnings? - Defense World
What is HC Wainwright's Forecast for CRVS FY2024 Earnings? - MarketBeat
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives $12.83 Consensus Price Target from Analysts - Defense World
Analysts Set Expectations for CRVS Q4 Earnings - Defense World
Drug Innovator Launches Pivotal Cancer Trial Breakthrough - Streetwise Reports
What is HC Wainwright's Estimate for CRVS Q4 Earnings? - MarketBeat
State Street Corp Purchases 57,943 Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) - Defense World
Corvus Pharmaceuticals (NASDAQ:CRVS) Now Covered by Analysts at HC Wainwright - Defense World
Corvus wins new buy from H.C. Wainwright despite recent selloff - MSN
Corvus stock wins new buy at H.C. Wainwright (CRVS:NASDAQ) - Seeking Alpha
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
This Kopin Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Corvus Pharmaceuticals (NASDAQ:CRVS) Coverage Initiated at HC Wainwright - MarketBeat
When the Price of (CRVS) Talks, People Listen - Stock Traders Daily
XTX Topco Ltd Buys Shares of 14,086 Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) - Defense World
Corvus falls after early-stage data for eczema therapy - MSN
Corvus Pharmaceuticals (NASDAQ:CRVS) Announces Interim Data from Atopic Dermatitis TrialBURLINGAME, Calif. – Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) disclosed key interim data from its randomized, double-blind, placebo-controlled Phase 1 cl - Defense World
Corvus: Early Atopic Dermatitis Data Signals More Questions Than Answers (Rating Downgrade) - Seeking Alpha
Corvus Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:CRVS) - Defense World
Why Is Corvus Pharmaceuticals Stock Trading Lower On Wednesday? - AOL
Corvus Pharmaceuticals: Not Just A One-Hit Wonder In ITK Inhibitor Targeting (CRVS) - Seeking Alpha
Crude Oil Gains Over 1%, General Mills Shares Fall - Benzinga
Dow Surges 150 Points, US Current Account Deficit Widens In Q3 - Benzinga
Stock Traders Buy High Volume of Put Options on Corvus Pharmaceuticals (NASDAQ:CRVS) - MarketBeat
Corvus stock falls after eczema trial data (CRVS:NASDAQ) - Seeking Alpha
Heico, Corvus Pharmaceuticals, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Corvus Pharmaceuticals Reports Promising Phase 1 Data and Financial Boost - TipRanks
Corvus Pharmaceuticals Shares Surge 7% After Positive Phase 1 Trial Results for Soquelitinib in Atopic Dermatitis - mediahousepress
Corvus Pharmaceuticals Inc Stock (CRVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Corvus Pharmaceuticals Inc Stock (CRVS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| MILLER RICHARD A MD | President and CEO |
May 06 '24 |
Buy |
1.73 |
577,634 |
1,000,000 |
577,634 |
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):